Effect of flecainide on the extension and localization of complex fractionated electrogram during atrial fibrillation

AIMS

Complex fractionated electrogram (CFE) ablation in addition to pulmonary vein isolation is an accepted strategy for the treatment of non-paroxysmal atrial fibrillation (AF). We sought to determine the effect of flecainide on the distribution and extension of CFE areas.

METHODS

Twenty-three non-paroxysmal AF patients were enrolled in this prospective study. A first CFE map was obtained under baseline conditions by sampling 5 s of continuous recording from the distal electrodes of the ablation catheter. Intravenous flecainide (1 mg/kg) was administered over 10 min and followed by 30-min observation time. A second CFE map was obtained with the same modalities. CFE-mean values, CFE areas, and atrial electrogram amplitude were retrieved from the electro-anatomical mapping system (Ensite NavX).

RESULTS

After flecainide administration, CFE-mean values increased (111.5 ± 55.3 vs. 132.3 ± 65.0 ms, p < 0.001) with a decrease of CFE area (32.9%) in all patients. Atrial electrogram amplitude decreased significantly (0.30 ± 0.31 vs. 0.25 ± 0.20 mV, p < 0.001). We observed 80.9% preservation of CFE areas. A CFE mean of 78 ms was the best cutoff for predicting stable CFE areas.

CONCLUSIONS

Flecainide reduces the extension of CFE areas while preserving their spatial localization. A CFE-mean value <80 ms may be crucial to define and locate stable CFE areas.

Long-term outcomes of adjunctive complex fractionated electrogram ablation to pulmonary vein isolation as treatment for non-paroxysmal atrial fibrillation

PURPOSE

The adjunctive ablation of areas of complex fractionated electrogram (CFE) to pulmonary vein isolation (PVI) is an emerging strategy for patients with non-paroxysmal atrial fibrillation (AF). We studied the long-term outcomes of this approach.

METHODS

Sixty-six patients (mean age 58 ± 9, 86.4 % male) with non-paroxysmal AF underwent ablation procedures consisting of PVI plus extensive CFE ablation. Post-ablation atrial tachycardia (AT) was also targeted if presented. All patients were followed up regularly on an ambulatory basis by means of ECG and Holter recordings.

RESULTS

After a mean follow-up period of 40 ± 14 months and 1.7 ± 0.7 procedures, 38 patients (57.6 %) were free of arrhythmias, 15 (22.7 %) displayed clinical improvement and 13 (19.7 %) suffered recurrences of persistent AF/AT. Females displayed poorer long-term outcomes than males (arrhythmia-free 22.2 vs. 63.2 %, p < 0.05). Multivariate analysis demonstrated that long duration of uninterrupted AF prior to the procedure was an additional predictor of long-term failure (odds ratio 1.49, p < 0.01). ROC analysis (area under curve 0.80; p < 0.001) estimated 3.5 years as the optimal cut-off point for predicting long-term failure (sensitivity 85 %, specificity 74 %). The cumulative data showed a significantly higher percentage of arrhythmia-free patients when the duration of AF had been ≤ 2 years (69.7 %) and ≤ 4 years (68.9 %) than when it was > 4 years (33.3 %; p < 0.01).

CONCLUSIONS

PVI + CFE ablation in non-paroxysmal AF appears to provide a reasonable proportion of arrhythmia-free patients during long-term follow-up. Poorer long-term results can be expected among female patients and those with an uninterrupted AF duration of > 4 years.

Ventricular arrhythmias originating from the aortomitral continuity: an uncommon variant of left ventricular outflow tract tachycardia

AIMS

Ventricular arrhythmias arising from the fibrous rings have been demonstrated, but knowledge about the aortomitral continuity (AMC) as a source of the arrhytmias is still limited. The objective is to describe the characteristics of ventricular arrhythmias originating from the AMC in patients without structural heart disease.

METHODS AND RESULTS

Ten patients with ventricular tachycardia (VT) and/or premature ventricular contractions, who had been successfully treated by catheter ablation at the AMC beneath the aortic valve, were enrolled. Clinical data and electrocardiographic characteristics were analysed. Three of the 10 patients had previously registered episodes of supraventricular tachycardia and had undergone catheter ablation of atrioventricular nodal reentrant tachycardia (AVNRT). In four patients with anterior AMC location, early R/S wave transition was found in the precordial leads, with equal R and S amplitudes in V2, rS in V1, and R in V3. In six patients whose VT arose from the middle part of the AMC, we demonstrated a special ('rebound') transition pattern, with which equal R and S amplitudes occurred in V2, and high R waves in V1 and V3. In the anterior AMC location, the S/R ratios in leads V1 and V2 were >1 and statistically significantly higher than those located in the middle (V1: 1.59 vs. 0.23, P< 0.001; V2: 1.52 vs. 0.41, P< 0.01).

CONCLUSIONS

We report a series of ventricular arrhythmias arising from the AMC with different R/S wave transition patterns in the precordial leads on the electrocardiogram. There may be a relationship between ventricular arrhythmias from AMC and AVNRT.

Remote magnetic versus manual catheters: evaluation of ablation effect in atrial fibrillation by myocardial marker levels

Background

A remote magnetic navigation (MN) system is available for radiofrequency ablation of atrial fibrillation (AF), challenging the conventional manual ablation technique. The myocardial markers were measured to compare the effects of the two types of MN catheters with those of a manual-irrigated catheter in AF ablation.

Methods

AF patients underwent an ablation procedure using either a conventional manual-irrigated catheter (CIR, n = 65) or an MN system utilizing either an irrigated (RMI, n = 23) or non-irrigated catheter (RMN, n = 26). Levels of troponin T (TnT) and the cardiac isoform of creatin kinase (CKMB) were measured before and after ablation.

Results

Mean procedure times and total ablation times were longer employing the remote magnetic system. In all groups, there were pronounced increases in markers of myocardial injury after ablation, demonstrating a significant correlation between total ablation time and post-ablation levels of TnT and CKMB (CIR r = 0.61 and 0.53, p < 0.001; RMI r = 0.74 and 0.73, p < 0.001; and RMN r = 0.51 and 0.59, p < 0.01). Time-corrected release of TnT was significantly higher in the CIR group than in the other groups. Of the patients, 59.6% were free from AF at follow-up (12.2 ± 5.4 months) and there were no differences in success rate between the three groups.

Conclusions

Remote magnetic catheters may create more discrete and predictable ablation lesions measured by myocardial enzymes and may require longer total ablation time to reach the procedural endpoints. Remote magnetic non-irrigated catheters do not appear to be inferior to magnetic irrigated catheters in terms of myocardial enzyme release and clinical outcome.

[Magnetic navigation for ablation of cardiac arrhythmias]

BACKGROUND

The first use of magnetic navigation for radiofrequency ablation of supraventricular tachycardias, was published in 2004. Subsequently, the method has been used for treatment of most types of tachyarrhythmias. This paper provides an overview of the method, with special emphasis on usefulness of a new remote-controlled magnetic navigation system.

MATERIAL AND METHODS

The paper is based on our own scientific experience and literature identified through a non-systematic search in PubMed.

RESULTS

The magnetic navigation system consists of two external electromagnets (to be placed on opposite sides of the patient), which guide an ablation catheter (with a small magnet at the tip of the catheter) to the target area in the heart. The accuracy of this procedure is higher than that with manual navigation. Personnel can be quickly trained to use remote magnetic navigation, but the procedure itself is time-consuming, particularly for patients with atrial fibrillation. The major advantage is a considerably lower radiation burden to both patient and operator, in some studies more than 50 %, and a corresponding reduction in physical strain on the operator. The incidence of procedure-related complications seems to be lower than that observed with use of manually operated ablation catheters. Work is ongoing to improve magnetic ablation catheters and methods that can simplify mapping procedures and improve efficacy of arrhythmia ablation. The basic cost for installing a complete magnetic navigation laboratory may be three times that of a conventional electrophysiological laboratory.

INTERPRETATION

The new magnetic navigation system has proved to be applicable during ablation for a variety of tachyarrhythmias, but is still under development.

Complications with permanent endocardial electrode systems

The different complications of endocardial electrode systems in 185 patients during the last seven years are discussed. The surgical technique for the now routinely used cephalic route is described. The choice of anaesthesia is discussed. In the last 39 implantations there have not been any displacements or retractions. Of the total number of patients only 3 required replacement of endocardial by myocardial electrodes. This was caused by unstable position and high stimulation threshold. Fracture of the electrode occurred in 4 cases. Stimulation of the diaphragm occurred in 10%, displacement and retraction of the electrodes in 6,5% and heart penetration or perforation in 3,8% of the patients. There was one death from cardiac tamponade due to electrode perforation of the right ventricle. One case had irreversible brain damage due to prolonged asystole during pulse generator replacement. Unimportant wound infections and haematomas occurred in 5 patients and phlebitis in 3 patients. More or less serious electrode complications have been seen in 56 of the 185 patients, 18 patients having more than one complication.

Patients with high-grade atrioventricular block treated and not treated with a pacemaker

One-hundred and eighty-one patients with chronic and with intermittent high-grade atrioventricular block (AVB) were studied retrospectively. Seventy-one were treated with fixed-rate, 51 with demand-type pacemaker, 59 were treated conservatively. Observation time was three years minimum and 14.5 years maximum. The mean age was about seven years higher, and 8.7% more patients had chronic AVB in the conservatively treated than in the pacemaker-treated group. About 12% more patients had Adams-Stokes attacks in the pacemaker group than in the conservatively treated group. There were 7% more patients with coronary heart disease (CHD) in the pacemaker group, and 10% more with aortic valve disease among the conservatively treated. Totally 4.4% of the patients had a calcification of the mitral annulus fibrosus. The two groups were comparable as regards functional class (NYHA) and heart size. Survival showed 31% more sudden deaths in the conservatively treated than in the pacemaker group. Sudden deaths were not more frequent among the patients with CHD than in those without. Long-term survival showed the more favourable result for the patients with than without pacemaker treatment. There were eight (11.3%) unexplained sudden deaths among the patients treated with fixed-rate pacemaker, only three (5.9%) among those treated with a demand unit. The fixed-rate and the demand units showed a mean longevity of 37.2 and 34.6 months, respectively.

Sudden death caused by heart block in a patient with multiple myeloma and cardiac amyloidosis

A patient with multiple myeloma and amyloidosis was admitted to hospital following successful cardiopulmonary resuscitation at home. No disturbances in heart rhythm were seen during the first 48 hours of continuous telemetric ECG recording. The patient died from ventricular asystole due to complete atrioventricular block, while he was on a 24-hour Holter monitoring the fifth night in hospital. Patients with known cardiac amyloidosis and syncope should undergo long-term ECG recordings, preferably by telemetry. Repeated registrations may be necessary to discover disturbances in heart rhythm.

Acute hemodynamic and long-term clinical effects of prazosin in the treatment of chronic congestive heart failure

The effect of prazosin in congestive heart failure was assessed in 10 patients (age 39--69) years) with ischemic heart disease or cardiomyopathy in functional class II-IV (NYHA). All patients were treated with digitalis and diuretics in optimal doses. Mean (+/- S.E.M.) cardiac index (CI) was 2.2 +/- 0.2 l/min/m2 before and 2.3 +/- 0.1 one hour after oral administration of 2--4 mg prazosin (given as tablets) (p less than 0.10). Mean pulmonary capillary wedge pressure (PWP) fell from 24 +/- 4 to 20 +/- 4 mmHg (p greater than 0.10). Prazosin seemed to have a more beneficial effect on patients with markedly elevated PWP or reduced CI before prazosin administration. The effect of prazosin on heart rate and systolic blood pressure was insignificant. During a follow-up period of 1--20 months (mean 7.3), 2 of 7 patients treated with prazosin (2--4 mg daily) improved their clinical condition, one patient was unchanged and 4 patients died in progressive cardiac failure. The results indicate that some patients with severe heart failure may benefit from prazosin when conventional treatment has failed.

Permanent pacemaker treatment in older age groups

Of 693 patients on permanent pacemaker treatment between 1962 and 1981, 282 (40.7%) were above the age of 75. Of this number, 142 patients were 75-79 years, 95 80-84 years and 45 85-93 (mean 87) years old at the time of the first pacemaker implantation. The patients were followed for 13-154 months (mean 37.1) with special attention being paid to morbidity and mortality after the implantation. Complications occurred in 65 (23%) of the elderly patients, with no significant difference between the three age groups. Excessive threshold rise with stimulation failure (6%) and infections or skin erosions (4.9%) were the most frequent complications. Mortality increased in all age groups during the first 6-12 months compared with the age- and sex-matched Norwegian population. Five-year survival rates were 56, 32 and 25% respectively. We conclude that cardiac pacemaker treatment in the elderly is a safe symptom-relieving therapeutic procedure and that the prognosis for these patients is similar to that for their fellow senior citizens after the first year of treatment.

Sick sinus syndrome treated with permanent pacemaker in 109 patients. A follow-up study

During the last decade implantation of permanent pacemakers has become the treatment of choice for patients suffering from the sick sinus syndrome (SSS). We have followed up 112 SSS patients treated with permanent pacemakers in Haukeland Hospital in the period 1966--76. The pacemakers were later removed from three of the patients. In the remaining 109 patients the SSS was characterized by tachy-bradyarrhythmias (TBA) in 44 and bradyarrhythmias (BA) in 65. Before implantation, 68 patients had syncopes and 27 severe dizziness. After implantation, symptomatic improvement was apparent in 104 patients; only three still had syncopes. During the follow-up period (mean 34.4 months), 29 patients died (yearly mortality 9.3%). There was no significant difference in total mortality between patients with TBA and with BA. Concomitant disturbances in atrioventricular (AV) conduction occurred in 35.8% of the patients. Among 79 of 80 patients still alive, five had developed total AV block, 19 had stable atrial fibrillation, 12 of these were possibly pacemaker-independent (ventricular rate greater than 60/min). Systemic embolization was observed in 16 patients, more frequently in the TBA (12/44) than in the BA group (4/65) (p less than 0.001). It is concluded that permanent pacemakers have an excellent symptomatic effect in patients with SSS. The prognosis is mainly determined by the presence or absence of coronary heart disease and/or heart failure.

Interference with cardiac pacemaker function

A survey is given of the factors affecting cardiac pacemaker function. Whereas it was earlier considered that external interference was a frequent cause of a pacemaker failure, more recent studies indicate that this is of minor importance. It would appear that failure of pacemaker function due to changes in the QRS-complex, i.e. voltage change, intraventricular conduction defects and frequency changes, intraventricular conduction defects and frequency changes, are more important. A lesser known cause of failure in demand function is the inhibition which arises from skeletal muscle postentials. This appears to be a major problem in some types of pacemaker. Manufacturing defects are unavoidable, and it can still be assumed that electronic component defects may develop in 1 of 1000 pulse generators. Cases with the problem of early run-away pacemaker are still being reported and two such cases are discussed. In one of the patients the run-away phenomenon was intermittent, and was accompanied by a variation in run-away frequency. This possibility should thus always be taken into consideration in a pacemaker patient presenting with snycope. In a patient with a QRS-inhibited pacemaker a double stimulation phenomanen has been observed.

Atrio-pulmonary vein conduction delay during pulmonary vein isolation for atrial fibrillation is related to vein anatomy, age, and focal activity

BACKGROUND

During pulmonary vein isolation for treatment of atrial fibrillation (AF), a significant delay in atrio-pulmonary vein (PV) conduction is often observed. We sought to investigate this conduction delay in various PV in individual patients.

METHODS

We studied 385 AF patients (mean age: 54 +/- 11 years, 74 women) who underwent segmental PV isolation (PVI). A circular decapolar catheter was used to record electrograms at the PV ostia. The time delay from local atrial potential to PV potential was measured in each vein. Conduction delay (CD) was defined as the longest time interval >20 ms observed during PVI.

RESULTS

For patients treated for the first time, CD was more frequently observed in the left common and the right and left superior PVs (84.2%, 67.9%, and 66.2%, respectively) and less frequently in the left and right inferior and right middle PVs (54.3%, 40.0%, and 30.8%, respectively). Veins with CD required more ablation applications (12.4 vs 9.9) and a higher ablated segmental fraction (72.3% vs 63.7%). CD was observed in 75.2% (109/145) of the PVs in which focal activity was detected. Older patients had a higher incidence of PVs with CD than younger patients. There were no gender differences.

CONCLUSIONS

The incidence of CD was highest in the left common and superior PVs, in older patients and in PVs with focal activity. PVs with CD required more ablation applications and a larger area of ablation around the ostia. These observations were not found during repeat procedures.

[Catheter ablation of tachyarrhythmias in children and adolescents]

BACKGROUND

Catheter ablation has been increasingly applied in children and adolescents with tachyarrhythmias. The aim of this article is to assess the results of ablation therapy of tachycardias in patients below 18 years of age at Haukeland University Hospital.

MATERIAL AND METHODS

141 patients (70 boys and 71 girls, aged 5-17 (13.5 +/- 3.5 ) years with tachyarrhythmias underwent an electrophysiologic study and catheter ablation in the period 1992-2007.

RESULTS

Ablation was successfully performed in 138/141 (98%) patients., The procedure was repeated (3 patients twice) until the arrhythmia substrate disappeared in 16 of 138 patients. 81/141 (57%) patients had accessory pathways; 52 (37%) had double atrioventricular nodal pathways, 48 had concealed and 33 patients had overt (classical Wolff-Parkinson-White-syndrome) atrioventricular pathways. 8 (6%) patients had other atrial or ventricular tachyarrhythmias and 4 (3%) had organic heart disease. Use of a 3D mapping system was decisive for success for ablation in patients with complex cardiac diseases. Procedure-related complications were observed in 2/141 (1.4%) patients of whom one had a temporary third degree and one had a permanent first-degree atrioventricular block which did not entail further treatment.

CONCLUSION

Catheter ablation of tachycardia in children and adolescents is a safe treatment method with a high success rate and few complications and should be preferred before drug therapy.

Significance of Late Recurrence of Atrial Fibrillation during Long-Term Follow-Up after Pulmonary Vein Isolation

BACKGROUND AND STUDY OBJECTIVE

Patients with paroxysmal or persistent atrial fibrillation (AF) can be treated by pulmonary vein (PV) isolation. Although the recurrence rate after the procedure is relatively high, the long-term outcomes after initially recurrence-free procedures remains unclear. We examined the rates of recurrence of AF after PV isolation.

METHODS

Our study included 278 consecutive patients with drug-refractory AF (mean age = 53 +/- 11 years, 228 men). PV isolation was based on the disappearance of PV potentials recorded from a circumferential catheter after segmental ostium ablation. Cavo-tricuspid isthmus lines and additional atrial lines were performed in 124 and 28 patients, respectively. Patients were monitored for a mean of 26 +/- 11 months (range 12-56). Recurrence was defined as >/= 1 episodes of symptomatic or asymptomatic AF > 1 month after the procedure.

RESULTS

A total of 120 (34) patients had >/= 1 recurrence of AF > 1 month after the procedure, of whom 14 (4) had a first recurrence > 6 months after the procedure. There was a significantly higher recurrence rate among patients with persistent AF.

CONCLUSIONS

A relatively high AF recurrence rate was observed after PV isolation. AF may recur late after the ablation procedure, though the majority of recurrences occurred within 6 months after the first procedure. There were no differences in incidence or time of occurrence of late recurrences between patients with paroxysmal versus persistent AF.

Device treatment of atrial tachycardia—minor additional effect of repeating pacing sequences

PURPOSE

Ramp and burst pacing as treatment for atrial tachycardia (AT), one known trigger mechanism of atrial fibrillation (AF) are available in permanent pacemakers to reduce the burden of AF. An analysis of the success rate of three consecutive antitachycardia pacing sequences is presented.

METHOD

The AT 500 (Medtronic) pacemaker was implanted in 36 patients (18 female, mean age 77+/-11 years) with pacemaker indication due to tachybrady arrhythmias (n=34), and other indications (n=2). A standardized AT treatment of 8 sequences of ramp followed by six and four sequences burst pacing was programmed on after 1 month of tachycardia detection only. 5 consecutive sinus beats or 3 min with atrial rhythm not classified as AF or AT defined treatment success and was registered at 3 months follow-up.

RESULTS

2979 episodes (mean 85+/-316) in 17 patients (7 female) were treated and analyzed. The overall treatment success increased from 42+/-27% to 44+/-31% and 45+/-31% during the consecutive ATP sequences (ns). The average ATP success of the first ramp pacing sequences was 95+/-10%, the second ramp ATP sequence was successful in 3+/-6%, and the last ramp ATP sequence in 2+/-5%.

CONCLUSION

95% of the 45% treatment success of a standard AT treatment was achieved by the first ramp pacing sequence. Further antitachycardia pacing sequences did not increase the success rate significantly.

A clinical study of patients with and without recurrence of paroxysmal atrial fibrillation after pulmonary vein isolation

Patients with paroxysmal atrial fibrillation (PAF) can be treated by pulmonary vein (PV) isolation. However, the recurrence rate after this procedure is relatively high. We sought to evaluate the quality of life (QOL) of patients with PAF recurrence after PV isolation and to analyze factors related to recurrences. Seventy-two drug-refractory PAF patients (59 men, 13 women, mean age 52 +/- 10) were included. PV isolation was based on the disappearance of PV potentials recorded from a Lasso catheter after segmental ostium ablation. Automatic foci were observed in 47 patients (65.3%) during the procedure. A mean of 3.1 +/- 0.9 PVs was isolated. Patients were followed for a mean of 10.3 +/- 5.1 months, during which 27 experienced >1 episode of PAF. QOL was scored from 0 (situation before ablation) to 10 (no episode after ablation) based on a questionnaire completed by 69 patients (95.8%). QOL was judged very good in 26 patients (none with PAF recurrences), better in 30 (15 with PAF recurrences), unchanged in 11 (10 with recurrences), and worse in 2 patients with PAF recurrences. Longer histories of PAF and a lower percentage of patients with automatic foci identified during the procedure were observed in the group with, than in the group without recurrences (P < 0.05). PV isolation improved QOL in patients with PAF, including in patients with recurrences. The length of PAF history and observation of automatic foci may be of importance for recurrences of PAF during long-term follow-up.

Reducing atrial tachycardia and atrial fibrillation episodes with a prevention and treatment device and tailored treatment

BACKGROUND

Pacemaker treatment of known trigger mechanisms for atrial tachyarrhythmias (AT) and atrial fibrillation (AF) has shown reduction in the incidence of AF. A new arrhythmia management device, which included storage of AT/AF (for tailoring treatment) and three prevention algorithms and one for treatment, was examined in order to identify the influence on arrhythmia episodes over a 12-month follow-up (FU) period.

METHODS

Twenty-three consecutive patients with known tachybradyarrhythmias were examined. Seven patients had to be excluded (two outliers, four developed permanent AF, one had no detection algorithm turned on at implantation). The remaining 16 patients showed 2723 episodes (675 treated episodes) for evaluation of the effect on episodes/month/patient (e/m/p), treatment success, duration of episodes, circadian distribution and quality of life.

RESULTS

The AT/AF e/m/p were reduced from 37 +/- 102 e/m/p at 1-month FU to 16 +/- 48 e/m/p at 3-month FU, 15 +/- 48 e/m/p at 6-month FU and 10 +/- 28 e/m/p at 12-month FU (p < 0.05), according to fewer subjective symptoms. Treatment success remained stable during the observation period (29-40%). Only minor changes in the duration of episodes and the distribution of start times were observed.

CONCLUSION

Tailoring treatment by the pacemaker examined with several prevention and treatment algorithms reduces e/m/p and might be a promising supplement in the treatment of selected patients with known AT/AF and bradycardia.

Reverse remodelling of systolic left ventricular contraction pattern by long term cardiac resynchronisation therapy: colour Doppler shows resynchronisation

OBJECTIVE

To quantify long term effects of cardiac resynchronisation therapy (CRT) by biventricular pacing in patients with heart failure (HF).

METHODS

Regional changes in left ventricular (LV) contraction patterns effected by CRT in 19 patients with HF (12 with ischaemia; mean (SD) age 66 (9) years) with bundle branch block were examined by colour Doppler tissue velocity imaging (c-TVI). Time differences during main systolic tissue velocity peak (SYS) were compared in the basal and mid LV interventricular septum and in the corresponding LV free wall segments.

RESULTS

From baseline to long term (9.8 (3.0) months) CRT, ejection fraction increased from 21.8 (5.4)% to 30.8 (7.6)%, LV end diastolic diameter decreased from 7.6 (0.9) cm to 7.1 (0.8) cm, and end systolic diameter decreased from 6.4 (1.2) cm to 6.0 (1.2) cm (p < 0.05). LV peak tissue velocities were unchanged during follow up. At baseline, SYS in LV free wall was typically delayed by an average of 29 ms in the basal LV site and by 18 ms in the mid LV site. The regional movements of the LV free wall and interventricular septum were separated by an average of only 14 ms and -4 ms (p < 0.05) at the basal site and by -21 ms and -16 ms at the mid LV site during short term and long term CRT, respectively.

CONCLUSIONS

The improved haemodynamic functions observed during CRT may be explained by a significant resynchronisation of the regional LV movement pattern during long term follow up.

Feasibility of color doppler tissue velocity imaging for assessment of regional timing of left ventricular longitudinal movement

OBJECTIVE--The feasibility of color Doppler tissue velocity imaging (c-TVI) with a high time resolution of 10 ms for simultaneous measurement of the temporal characteristics of regional left ventricular (LV) tissue velocities at different LV sites was examined. Methods and results--In 20 subjects with structurally normal hearts, inter- and intraobserver agreement and the beat-to-beat variation were tested in c-TVI profiles from basal and mid-LV segments of the interventricular septum (IS) and of the lateral free wall (LFW). For peak tissue velocities a mean error of less than 1 cm/s was demonstrated. For systolic regional LV velocity time difference, the mean error was +/- 5 ms, with the best agreement when sampling from basal LV sites. For diastolic regional LV velocity time differences, the mean error was +/- 12 ms. The longitudinal LV movement pattern demonstrated a pattern of incremental tissue velocity from basal to mid-LV, and from IS to LFW sites. Conclusion--The c-TVI method has acceptable inter- and intraobserver agreement and is sufficiently accurate to disclose regional time aspects of LV contraction and relaxation.

Color Doppler Tissue Velocity Imaging Demonstrates Significant Asynchronous Regional Left Ventricular Contraction and Relaxation in Patients with Bundle Branch Block and Heart Failure Compared with Control Subjects

Bundle branch block in patients with severe heart failure (HF) may result in asynchronous regional left ventricular (LV) contraction. Colour Doppler tissue velocity imaging (c-TVI) allows tissue velocity profiles to be measured with a resolution of 10 ms. Normal subjects (n = 30) showed a synchronous regional longitudinal LV pattern of movement, and HF patients with bundle branch block (n = 30) showed asynchronous contraction and relaxation patterns which were quantified by c-TVI as ranging from -22 to 19 ms. This asynchronous LV contraction probably contributes to the deterioration of LV function in HF patients.

Color Doppler tissue velocity imaging can disclose systolic left ventricular asynchrony independent of the QRS morphology in patients with severe heart failure

A QRS width greater than 120 ms is assumed to be a marker of inter- and intraventricular asynchrony in severe heart failure (HF) patients. Color Doppler tissue velocity imaging (c-TVI) with a time resolution of 10 ms was used to study regional left ventricular (LV) longitudinal systolic contraction pattern in HF patients with left and right bundle branch block (LBBB and RBBB) and in patients with normal QRS width. We studied 12 women and 23 men with severe HF, with a mean age of 66 +/- 11 years in New York Heart Association functional Class 2.9 +/- 0.6. Twenty patients had LBBB and 10 of those were accepted for cardiac resynchronization therapy by biventricular pacing (CRT). Ten patients had normal QRS width, and five had RBBB. In the echocardiographic apical four chamber view, regional peak LV tissue velocities and regional LV time differences of peak tissue velocities were compared at basal and mid-LV segments. There were no significant differences in regional mean peak tissue velocities among the patient groups. In patients with LBBB accepted for CRT, the LV lateral free-wall movement at basal LV was 29 ms delayed during main systole, almost significantly different from LBBB patients not accepted for CRT (P = 0.075). Even in HF patients with normal QRS width or RBBB, significant asynchronous longitudinal LV contraction was observed.

CONCLUSIONS

For the detection of regional longitudinal LV contraction asynchrony in patients with severe HF, supplementary methods to the surface ECG, such as c-TVI, are strongly recommended.

[Curative treatment of paroxysmal atrial fibrillation with radiofrequency ablation]

BACKGROUND

Atrial fibrillation is associated with increased morbidity and twice the mortality compared to individuals without fibrillation. Treatment with antiarrhythmic drugs has limited effect in paroxysmal atrial fibrillation.

MATERIAL AND METHOD

The group of patients comprised 59 men and 13 women with an average age of 51 +/- 10, the majority of whom had failed several drug regimens; some had undergone repeated DC conversions. A new method based on radiofrequency ablation and isolation of pulmonary veins from the left atrium may offer curative treatment for paroxysmal atrial fibrillation. The basis for this method is that foci in or close to the pulmonary veins initiate or drive atrial fibrillation. These foci may be identified by transseptal access to the left atrium and isolation of the veins from the left atrium using radiofrequency energy.

RESULTS

The group of 72 patients underwent 86 procedures. Foci were observed in 65.3%. Isolation of 3.1 +/- 0.9 veins was performed in 71 patients. During a follow up period of 10.3 +/- 5.1 months, 60.9% reported absence of fibrillation and 81.2% reported cure or considerable improvement. Complications included drainage of pericardial effusion in one patient, cerebral embolus with partial visual impairment in one patient, and an asymptomatic pulmonary vein stenosis in one patient.

CONCLUSION

Paroxysmal atrial fibrillation can be treated in selected patients using pulmonary vein isolation with low to moderate risk of complications. Longer follow up is necessary for full evaluation of effect.

Global Right Atrial Mapping Delineates Double Posterior Lines of Block in Patients with Typical Atrial Flutter:

Double Posterior Lines of Block in Typical Atrial Flutter.

INTRODUCTION

The crista terminalis (CT) has been shown to be a barrier to transverse conduction during typical atrial flutter (AFL). However, some studies have demonstrated the presence of functional block in the sinus venosa region but not at the CT. The aim of this study was to define these regions of block in the right atrium using a three-dimensional noncontact mapping system.

METHODS AND RESULTS

In 39 AFL patients (33 men and six women, mean age 56 +/- 13 years), a noncontact multielectrode array was used to reconstruct electrograms in the right atrium. Isochronal and isopotential propagation mapping was performed during AFL and during pacing from the coronary sinus ostium and the low lateral wall (cycle length from 600 to 240 msec) in sinus rhythm after creation of isthmus block. A single line of block along the CT area was found in 18 patients (46%). Two lines of block were found in 21 patients (54%), with the first line located along the CT area. The second was located in the sinus venosa region in 20 patients (51%) and in the lateral wall in 1 patient (3%). In all patients, the block in the lower part of the CT was observed during AFL (60%) and during pacing at all cycle lengths (48%-62%). The length and proportion of block were inversely proportional to pacing cycle length.

CONCLUSION

Double lines of block were frequently observed in patients with AFL, and both lines may form the posterior boundaries of the AFL circuit. Block was fixed in the lower part of the CT and was functional in the upper part of the CT.

Immediate control of life-threatening digoxin intoxication in a child by use of digoxin-specific antibody fragments (Fab)

Digoxin-immune antibody fragments (Fab) for treatment of digitalis intoxication was introduced in 1976. Many reports have been published concerning this therapy for children, but few have focused on its immediate reversal of cardiac as well as extracardiac life-threatening manifestations of digoxin toxicity. We present a case of life-threatening digitalis intoxication in a child with postoperative renal insufficiency, after a Sennings procedure for transposition of the great arteries. Digoxin administration according to the nationally recommended dosage and intervals unexpectedly resulted in serum levels in the toxic range. Severe cardiac arrhythmias, haemodynamic instability and a rapid-increasing serum potassium level resulted. This report demonstrates how administration of Fab according to the manufacturer's dosage recommendation reversed the tachyarrhythmia immediately and re-established a normal level of serum potassium within minutes.

Three-dimensional noncontact mapping defines two zones of slow conduction in the circuit of typical atrial flutter

The cavotricuspid isthmus (CTI) is a slow conduction area in the circuit of typical atrial flutter. However, conventional methods are limited by the inaccuracy of measurements of distance on the surface of the heart. The aim of the study was to define the conduction properties of the atrial flutter circuit along the tricuspid annulus by using a three-dimensional noncontact mapping system. In 34 atrial flutter patients (30 men, 4 women; mean age 54 +/- 14; 27 counter-clockwise, 4 clockwise, and 3 both), a noncontact multielectrode array was used to reconstruct electrograms in the right atrium. Isochronal and isopotential propagation mapping was performed during atrial flutter. The conduction velocity was calculated by dividing conduction time by surface distance. The right atrium along the tricuspid annulus was divided into five regions: lateral wall, superior right atrium, septum, septal CTI, and lateral CTI. Conduction velocities were 0.99 +/- 0.85, 1.67 +/- 1.21, 1.58 +/- 1.05, 0.82 +/- 0.72, and 1.68 +/- 1.00 m/s in counter-clockwise and 0.81 +/- 0.71, 2.61 +/- 1.90, 1.52 +/- 0.91, 0.91 +/- 0.80 and 1.91 +/- 0.83 m/s in clockwise, respectively. Conduction velocities were significantly slower in the septal CTI and lateral wall than in the lateral CTI, the septum, and the superior right atrium (P < 0.05). No significant difference was found between the septal CTI and the lateral wall. Conduction within the septal CTI was slower in patients treated with antiarrhythmic agents than in untreated patients (P < 0.05). The septal part of the CTI (but not the lateral CTI) and the lateral wall are slow conduction zones in the atrial flutter circuit, and both may, therefore, be mechanically important for the development of atrial flutter.

Identification of extremely slow conduction in the cavotricuspid isthmus during common atrial flutter ablation

INTRODUCTION

Complete isthmus block has been used as an endpoint for radiofrequency ablation for common atrial flutter (AF). We sought to systematically evaluate extremely slow conduction (ESC), which is easily misinterpreted as complete block.

METHODS AND RESULTS

We studied 107 consecutive patients (92 men, 15 women, 58 +/- 11 years) who had undergone a successful AF ablation procedure. A 24-pole catheter was positioned along the tricuspid annulus spanning the isthmus. Complete isthmus block was defined as the presence of a complete corridor of double potentials along the ablation line. Activation delay time (AT), activation difference (deltaA) between two adjacent dipoles, maximum activation difference (deltaA(max)), change in polarity (CP) and change in amplitude (CA) of the bipolar atrial electrogram were recorded and P-wave morphology in the surface electrocardiogram was analyzed. ESC was observed in 16 patients. Between ESC and complete block, differences were found on the two lateral dipoles adjacent to the ablation line (AT: 148 +/- 17 vs. 183 +/- 27 ms and 155 +/- 18 vs. 170 +/- 28 ms, P < 0.01; deltaA: -91 +/- 22 vs. -126 +/- 28 ms and -7 +/- 13 vs. 13 +/- 6 ms, P < 0.01). Statistically significant differences in CP were detected on the relevant dipoles (7/16 vs. 14/16 and 6/16 vs.13/16, P < 0.05). No significant difference was found either in CA or in terminal P wave positivity. Mean deltaA(max) were 13.8 +/- 5.0 and 27.8 +/- 9.5 ms (P < 0.001) respectively in ESC and complete block. Two types of ESC, regular and irregular, were demonstrated during the ablation procedure.

CONCLUSIONS

(1) ESC was observed in 15% of the patients during the AF ablation procedure. (2) The parameters of AT, deltaA, and CP may help to differentiate ESC from complete block. DeltaA(max) might be the most powerful indicator. (3) To verify complete block, it is essential to position the mapping catheter across the CTI in order to demonstrate the activation sequence up to the ablation line.

Acute resumption of conduction in the cavotricuspid isthmus after catheter ablation in patients with common atrial flutter. Real-time evaluation and long-term follow-up

AIMS

Cavotricuspid isthmus conduction (CIC) is closely associated with the maintenance and recurrence of common atrial flutter (AFL). This study systematically sought to assess the prevalence and characteristics of acute CIC recovery during AFL ablation and to define its predictors and its relationship with the results of long-term follow-up.

METHODS AND RESULTS

A total of 124 consecutive patients (105 men, 19 women, mean age 58 +/- 11 years) who underwent successful AFL ablation were included. The procedure endpoint was defined as complete bi-directional CIC block. During an observation period of 30 min, the incidence of CIC restoration was 34.% in patients and 39.8% in applications. It increased with increasing block time and decreased over time during the observation period. Block time in successful burns followed by persistent block was shorter than in those followed by CIC resumption (12 +/- 6 vs 33 +/- 12 s, P<0.0001). A negative correlation between block time and resumption time was found (r = - 0.57, P<0.001). Patients with permanent pacemakers had a higher incidence of acute CIC resumption than those without pacemakers (5/7 vs 29/117, P = 0.007). The AFL recurrence rate was 4.8% during a mean follow-up period of 21 +/- 8 months. Our results suggest that acute CIC resumption may be a potential risk for clinical AFL recurrence during long-term follow-up.

CONCLUSIONS

Acute CIC resumption in common AFL ablation varies in terms of incidence and time course. Block time has a predictive value for acute CIC recovery. Observation time can be shortened if block time is short. With longer block time, it is essential to observe for a longer period in order to minimize CIC resumption.

Alternate pacing sites for patients with tricuspid valve prostheses

The objective of this study was to pace via a coronary vein to avoid interfering with the tricuspid valve prosthesis function. Pacing leads were inserted into the posterior cardiac vein in a 68-year-old woman (patient 1), and in the great cardiac vein and the right auricle in a 32-year-old woman (patient 2). In patient 1 the stimulation threshold was 1.8 V at implant and stabilized at 3.0 V at the 24-month follow-up. In patient 2 the ventricular pacing threshold was 1.2 V at implant and stabilized at 0.7 V at the 24-month follow-up. The cardiac output at rest increased 43% during atrioventricular synchronous pacing compared to ventricular pacing. Long-term stable ventricular pacing via the coronary venous system was obtained.

[Atrial flutter--diagnosis and therapeutic possibilities]

BACKGROUND

Atrial flutter and atrial fibrillation are among the most common heart rhythm disturbances in the population, with an assumed prevalence of 1-2%. About 40,000-60,000 Norwegians endure such rhythm disorders, with an increasing occurrence in the elderly population.

MATERIAL AND METHODS

Surface ECG remains the corner-stone for the clinical diagnosis. We describe the various mechanisms, clinical presentation, and diagnosis based on modern invasive electrophysiological methods of atrial flutter.

RESULTS

The available therapeutic modalities for conversion during episodes and prophylaxis with drugs, various pacing techniques, DC conversion and surgical therapy are discussed.

INTERPRETATION

Radiofrequency catheter ablation is the only available method to cure the patient in a gentle manner.

[Biventricular pacemaker treatment of patients with severe heart failure]

BACKGROUND

Biventricular pacing using a pacemaker lead located epicardially on the left ventricle, introduced via the coronary sinus to a coronary vein, and one pacemaker lead located endocardially at the apex of the right ventricle can resynchronize the contraction of the left ventricle. Approximately 30-50% of patients with severe heart failure have left bundle branch block indicating asynchronous contraction of the left ventricle. These patients can have a significant haemodynamic benefit from biventricular pacing.

MATERIAL AND METHODS

The methods for implanting the leads are described. Biventricular pacemakers were implanted in five patients.

RESULTS

Acceptable low thresholds for pacing the left ventricle were achieved. Resynchronization of the contraction of the left ventricle was demonstrated by using colour tissue Doppler measurements. The mechanisms for the haemodynamic benefit of biventricular pacing are discussed on the basis of our data. The first patient has been followed for 12 months. He has a lasting improvement in functional capacity from class IV to class II, marked reduction of the left ventricular size, and improvement of the left ventricular ejection fraction from 15% to 38%.

INTERPRETATION

The results are promising for patients who, because of lack of donor hearts and age criteria, often cannot be offered heart, transplantation.

[Radiofrequency catheter ablation of atrial flutter]

BACKGROUND

The anatomical structure of atrial flutter is now well recognized, and treatment with radiofrequency catheter ablation (RFA) is established. Several recording and ablation techniques can be applied.

MATERIAL AND METHODS

An increasing number of patients have been treated with RFA at the Arrhythmia Centre at Haukeland University Hospital over the last six years. During the two-year period 1999 and 2000, a total of 108 procedures were performed for atrial flutter in a total of 84 patients. A total of 543 RFA procedures for various forms of re-entry tachycardias were performed during the same period; hence, atrial flutter comprised about 20% of RFA procedures. Altogether 71 men and 14 women with a mean age of 57 +/- 12 years were treated. The mean history of atrial flutter had a duration of nine years, maximum 43 years with several hospital admissions, drug trials, overdrive pacing and DC conversion until they were ultimately cured with RFA.

RESULTS

The success rate during first time treatment was 96.5%. No serious complications were observed.

INTERPRETATION

RFA should be the treatment of first choice in patients with recurrent or incessant atrial flutter.

RV function in stable and unstable VT: is there a need for hemodynamic monitoring in future defibrillators?

During electrophysiological investigation of 22 patients with VT or aborted sudden cardiac death, arterial and RV pressures were measured. The time courses of mean arterial pressure (MAP), RV pulse pressure (RVPP), RV pulse pressure integral (RVPPI), and maximum right ventricular dP/dt (RV dP/dtmax) were followed during the first 15 seconds after VT induction. Compared to basal (preinduction) conditions, the RVPPI decreased by 41+/-10% (mean +/- SD) after 10-15 seconds of VT in 11 patients with stable VT and by 75+/-8% in 11 patients with unstable VT (MAP < 60 mmHg 15 s after VT onset). RVPP decreased by 13+/-11% after 10-15 seconds of VT in the stable VT group and by 50+/-16% in the unstable VT group. For RV dP/dtmax, these decreases were 4+/-22% in the stable VT group and 37+/-24% in the unstable VT group. There was a good correlation between percent decrease in MAP and percent decrease in RVPPI, RVPP, and RV dP/dtmax at 5-10 seconds (r = 0.86, 0.81, and 0.73, respectively) and 10-15 seconds (r = 0.84, 0.82, and 0.69, respectively) after VT onset. There was hardly any overlap of distributions of the individual values with the RVPPI parameter between the two VT groups. Comparing and correlating the percent decrease in mean arterial pressure with the RVPPI, RVPP, and RV dP/dtmax during induced VT, RVPPI demonstrated the most significant and specific changes in discriminating stable from unstable rhythms. However, by comparing RVPPI and RVPP using the area under the receiver operating characteristic curves, there was no significant statistical difference between the two parameters. By integrating rate criteria, electrogram signal analysis, and RVPPI or RVPP as a hemodynamic criterion, detection and treatment algorithms could improve the performance of future implantable defibrillators and avoiding shocks in VTs that can be terminated by antitachycardia pacing.

A typical P-wave morphology in incessant atrial tachycardia originating from the right upper pulmonary vein

Automatic atrial tachycardias often originate from the ostia of the pulmonary veins. P-wave morphology during tachycardia may indicate from which pulmonary vein the tachycardia originates. Two patients with pulmonary vein tachycardias demonstrating atypical P-wave morphology were investigated. One of the patients had a tachycardia with two different cycle lengths. P-wave morphology was evaluated in 12-lead ECGs from two patients with incessant atrial tachycardia, during tachycardia and sinus rhythm. Their tachycardias were successfully ablated at the mouth of the right upper pulmonary vein. Previous studies have demonstrated a positive or negative P-wave configuration in lead aVL originating from this area and a change from a biphasic P-wave in V1 during sinus rhythm to a positive P-wave configuration during tachycardia. Neither of our two patients had such a change in lead V1. One our patients had two tachycardias with different cycle lengths originating from the same area. It is concluded that if an atrial tachycardia with P-wave morphology resembling that of sinus rhythm cannot be located to the right atrium, its origin may be the right upper pulmonary vein.

Pacing threshold trends and variability in modern tined leads assessed using high resolution automatic measurements: conversion of pulse width into voltage thresholds

With the aid of an algorithm for automatic pacing threshold (T) measurement in the atrium and ventricle, downloadable into implanted Thera pacemakers (Medtronic Inc.), we studied T evolution during lead maturation, T variation during activities of daily living, and various types of beat-to-beat T variations in three tined bipolar leads: 5.6-mm2 steroid-eluting (Medtronic Inc. models 4524 atrial-J [n = 8] and 4024 ventricular [n = 8]), 1.2-mm2 steroid-eluting (Medtronic Inc. models 5534 atrial-J [n = 9] and 5034 ventricular [n = 9]), and 8-mm2 without steroid (Intermedics models 432-04 atrial-J [n = 7] and 430-10 ventricular [n = 7]). The leads were implanted in 24 consecutive patients with intact AV conduction (required by the algorithm) and followed for up to 13-25 months after implantation. Since the algorithm determined pulse width Ts at different amplitudes that, depending upon T level, could range from 0.5 to 5.0 V, we invented a methodology for conversion of pulse width Ts into voltage Ts at 0.5 ms, to pool and present T data on a universal scale. Frequent, high resolution T measurements revealed details on the lead maturation process that we divided into three stages: initial T subsiding, first wave of T peaking, and a new, quicker or slower, T rise. Although there were notable differences in duration and magnitude of T peaking on the individual basis, differences between the three lead types and between the atrium and ventricle were demonstrable. The 1.2-mm2 leads exhibited less T peaking than their predecessors 5.6-mm2 leads and excellent positional stability, whereas 8-mm2 leads demonstrated the most intensive T peaking and highest mean chronic T values. T changes during activities of daily living showed some tendencies-higher T during night and lower T during exercise--yet with a number of exceptions. The overall magnitude of daily T fluctuations was < 0.2 V in all but one lead, and 50% daily voltage safety margin would be sufficient. A 100% voltage safety margin may be inadequate for a 1-year period during the chronic phase (after 6 months of implantation). A scheme for calculation of pulse width safety margins equivalent to voltage safety margins is given. Some leads can exhibit very large beat-to-beat T variations before, during, and after T peaking, and prospective algorithms for automatic T measurement should verify T values through more than 1-2 captured beats to obviate a great underestimation of the T providing consistent capture. T dependence upon pacing rate was negligible. Consistent-capture hysteresis may, in conjunction with lead instability, be as much as 0.25 V. Therefore, it is better to use an incremental approach from below to T level during automatic T measurements.

Clinical use of low output settings in 1.2-mm2 steroid eluting electrodes: three years of experience

A new generation of tined steroid-eluting leads featuring 1.2-mm2 distal electrodes (CapSure Z, Medtronic Inc., Minneapolis MN, USA) has the potential to reduce battery current drain and enhance pulse generator longevity by means of high pacing impedance and low pacing threshold. Forty patients aged 50-87 years (mean 72.4 years) were implanted with 33 ventricular (models 4033 and 5034) and 30 atrial-J (models 4533 and 5534) leads with 1.2-mm2 electrodes. Low pacing outputs, mainly in the range from 1 V/0.20 ms to 1.6 V/0.36 ms with > or = 3:1 pulse width safety margins (PWSM) applied, were instituted at 3-6 months of implantation and adjusted at subsequent follow-up controls according to changes in thresholds. Cumulative follow-up period of low outputs was 1,512 months (24 months per lead, range 9-36 months), which involved 3.43 follow-up controls per lead (range 2-5). During follow-up, pulse width thresholds (PWTs) at the used amplitudes did not change in 55.5% of the leads; PWTs increased by < or = 100% in 36.5%, by 101%-200% in 1.6%, and by > 200% in 6.3% of the leads. Changes in PWT that would apparently exceed 3:1 PWSM over a 1-year period occurred in one atrial lead where even the nominal 3.5 V/0.4-ms output would not be effective and in one ventricular lead in the aftermath of an acute myocardial infarction (300% PWT rise at 1.6 V). Based on the present observations, pacemaker dependent patients require > or = 4:1 PWSM and other patients > or = 3:1 PWSM with output pulse widths < or = 0.60 ms and annual pacemaker clinic visits. Calculated battery current drain and anticipated longevity associated with a variety of pacing outputs and impedances are provided, compared, and discussed. Correlation between acute and chronic pacing impedances and pacing thresholds was weak, implying that a systematic intraoperative pacing site optimization cannot contribute significantly to the extension of average battery longevity.

Automatic adjustment of pacemaker stimulation output correlated with continuously monitored capture thresholds: a multicenter study. European Microny Study Group

Pacing threshold is affected by many factors. A pacing system able to confirm capture at each beat and automatically adjust its output close to the actual pacing threshold is highly desirable. This study evaluates the safety and efficacy of the Autocapture function of the Pacesetter Microny SR+. One hundred thirteen patients were recruited from 16 centers in 7 European countries and followed up for 1 year. All pacemakers were implanted with Pacesetter's low polarization, bipolar leads. The key feature of Autocapture is the immediate delivery of a 4.5 V safety backup pulse 62.5 ms after any ineffective ongoing low output pulse. Holter recordings confirmed total reliability of this feature without any exit block. The measured evoked response (ER) signal was stable over time. Acute and chronic pacing thresholds measured by VARIO and Autocapture tests correlated (r > 0.79) over the period of the study. The incidence of backup pulses was 1.1% during pacing. With Autocapture programmed ON, the overall total current consumption was 4.1 microA for VVI and 5.0 microA for VVIR pacing. This study proved that the Autocapture safely and reliably regulates the pacemaker's output according to the prevailing threshold thus providing maximum patient safety and prolonging service life.

Pacing impedance variability in tined steroid eluting leads

The aim of the study was to investigate pacing impedance (PI) behavior in ambulatory patients. Eighteen atrial and 18 ventricular tined steroid eluting leads with 1.2-mm2 and 5.6-mm2 electrodes were implanted in 20 patients. At 9-27 months after implantation PI was measured automatically by means of additional algorithms downloaded via telemetry links into implanted Thera pulse generators. PI was determined based on the voltage drop on the output capacitor during the 5 V-1 ms pacing impulse, at the programmable sampling rates from 1 second to 30 minutes. The study examined in particular: (1) PI trends and variations associated with different breathing patterns, body postures, provocative maneuvers, bike exercise, and during 24 hours; (2) impact of pacing rate and AV-delay on PI; (3) correlation between PI variability and pacing threshold, lead configuration, absolute PI value, age, gender, disease, and cardiac chamber. The most important findings were: (1) large PI variations of up to 450 omega were observed in properly functioning leads, (2) PI variability exhibited a weak negative correlation with pacing thresholds as if electrode positional stability was not a major factor underlying PI variations, (3) unipolar and bipolar PI variations were equivalent to each other (correlation factor = 0.93) implying that PI was mostly dependent on the circumstances around the lead tip.

An algorithm for automatic measurement of stimulation thresholds: clinical performance and preliminary results

We have developed an algorithmic method for automatic determination of stimulation thresholds in both cardiac chambers in patients with intact atrioventricular (AV) conduction. The algorithm utilizes ventricular sensing, may be used with any type of pacing leads, and may be downloaded via telemetry links into already implanted dual-chamber Thera pacemakers. Thresholds are determined with 0.5 V amplitude and 0.06 ms pulse-width resolution in unipolar, bipolar, or both lead configurations, with a programmable sampling interval from 2 minutes to 48 hours. Measured values are stored in the pacemaker memory for later retrieval and do not influence permanent output settings. The algorithm was intended to gather information on continuous behavior of stimulation thresholds, which is important in the formation of strategies for programming pacemaker outputs. Clinical performance of the algorithm was evaluated in eight patients who received bipolar tined steroid-eluting leads and were observed for a mean of 5.1 months. Patient safety was not compromised by the algorithm, except for the possibility of pacing during the physiologic refractory period. Methods for discrimination of incorrect data points were developed and incorrect values were discarded. Fine resolution threshold measurements collected during this study indicated that: (1) there were great differences in magnitude of threshold peaking in different patients; (2) the initial intensive threshold peaking was usually followed by another less intensive but longer-lasting wave of threshold peaking; (3) the pattern of tissue reaction in the atrium appeared different from that in the ventricle; and (4) threshold peaking in the bipolar lead configuration was greater than in the unipolar configuration. The algorithm proved to be useful in studying ambulatory thresholds.

Atrial synchronous ventricular pacing with a single lead: reliability of atrial sensing during physical activities, and long-term stability of atrial sensing

A VDD pacing system with bipolar single-pass leads, were implanted in 36 consecutive patients (average age 72 +/- 2 years) with high degree atrioventricular block and normal sinus node function. At implant the atrial signal amplitude was 2.6 +/- 0.2 mV measured by a pacing system analyser (PSA), 1.8 +/- 0.1 mV measured peak-to-peak from the telemetered calibrated electrogram, and 1.3 +/- 0.1 mV measured from the sensing threshold. At one month follow-up the peak-to-peak amplitudes (mV) of the telemetered atrial electrograms were not significantly different measured continuously during resting supine with quiet breathing (1.4 +/- 0.1), sitting (1.6 +/- 0.2), standing (1.5 +/- 0.1), arm swinging (1.4 +/- 0.2), hyperventilation (1.3 +/- 0.1), Valsalva manoeuvre (1.4 +/- 0.1), and treadmill exercise (1.9 +/- 0.6). The telemetered atrial electrogram amplitude and the atrial sensing threshold varied between 1.2 +/- 0.09 mV and 1.8 +/- 0.1 mV, and between 0.95 +/- 0.07 mV and 1.3 +/- 0.01 mV, respectively at 0.5, 1, 3, 6 and 12 months follow-up, but the changes were statistically non-significant. The Event Summary showed sensing of 98% to 99% of the atrial events at the different follow-up periods.

Clinical performance of steroid-eluting pacing leads with 1.2-mm2 electrodes

To raise pacing impedance and reduce battery current drain, new tined steroid-eluting leads were developed with 1.2-mm2 hemispherical electrodes, instead of conventional 5-8 mm2. Twenty-two unipolar J-shaped atrial leads and 25 unipolar ventricular leads (models 4533 and 4033, respectively) were implanted in 33 consecutive patients and followed for a mean of 25 months (range 18-29). Handling characteristics of atrial leads were found favorable. The leads slipped easily into the right atrial appendage and were easy to position. Handling characteristics of ventricular leads were satisfying, but more efforts had to be applied to cross the tricuspid valve. Special care was taken to avoid perforation of the myocardium due to the small lead tip. Following implantation, four ventricular and one atrial lead exhibited instability of pacing thresholds that resolved spontaneously within 1-3 days of implantation. Except for this, no lead malfunctioned. The reoperation rate was zero. The mean electrogram amplitudes of 15 mV (ventricle) and 4 mV (atrium), and the mean chronic pacing threshold of 0.085 ms at 1.6 V (app. 0.43 V at 0.5 ms) were comparable with the best values seen in the literature on passive fixation leads. The rest of the electrophysiological parameters were enhanced: mean pacing impedances were 984 omega (acute) and 900 Q (chronic), mean slew rates 3.26 V/s (ventricle) and 1.75 V/s (atrium), mean acute voltage threshold at 0.5 ms was 0.25 V, mean current and energy thresholds calculated at 0.5 ms were 260 microA and 32 nJ (acute) and 478 microA and 103 nJ (chronic). The electrical characteristics of these leads provide for increased pacemaker longevity in combination with substantial safety margins for pacing and sensing.